Sean Laaman
Stock Analyst at Morgan Stanley
(4.75)
# 124
Out of 5,093 analysts
19
Total ratings
94.44%
Success rate
24.09%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $12.53 | +59.62% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $18.85 | +80.37% | 1 | Nov 21, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $44 → $45 | $41.87 | +7.48% | 4 | Nov 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $194 → $196 | $145.22 | +34.97% | 3 | Nov 4, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $91.68 | +25.44% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $246.52 | +23.32% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $318.69 | +20.18% | 2 | Oct 20, 2025 | |
| CERT Certara | Assumes: Equal-Weight | $16 | $9.17 | +74.48% | 1 | Jul 3, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $1.28 | +17.19% | 1 | Mar 7, 2025 | |
| HALO Halozyme Therapeutics | Assumes: Overweight | $67 | $61.87 | +8.29% | 1 | Feb 14, 2025 |
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $12.53
Upside: +59.62%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $18.85
Upside: +80.37%
Exelixis
Nov 5, 2025
Maintains: Overweight
Price Target: $44 → $45
Current: $41.87
Upside: +7.48%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $194 → $196
Current: $145.22
Upside: +34.97%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $91.68
Upside: +25.44%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $246.52
Upside: +23.32%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $318.69
Upside: +20.18%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $9.17
Upside: +74.48%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $1.28
Upside: +17.19%
Halozyme Therapeutics
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $61.87
Upside: +8.29%